Redx Pharma (REDX) has been given formal approval to restart its phase1/2a clinical trials of RXC004 for patients with advanced solid tumours.
RXC004 is a new porcupine inhibitor drug, that targets the Wnt signalling pathway, which is implicated in the maintenance of cancer stem cells in different types of cancer. The company stated that there is strong evidence that the pathway plays a key role in how tumours avoid detection from tumour fighting immune cells, which is promising for the development of treatments. .
Lisa Anson, Chief Executive Officer, Redx Pharma plc said: “We believe that the revised RXC004 clinical protocol and development plan has the potential to offer clinical benefit both as a monotherapy and in combination with standard of care treatments.”
Shares in Redx Pharma were up 10% following the news
The UK Medicines and Healthcare products Regulatory Agency (MHRA) gave Redx formal approval to re-commence trials for the drug with a lower starting dose, putting clinical evaluation back on track to resume in H1 2019.
Natalie Cook, Consultant Oncologist and Principal Investigator from the Christie Hospital in Manchester, UK commented: "We have learnt a significant amount from the first patient treated with RXC004, and this provides the basis for an optimised RXC004 development plan as well as the confidence to evaluate the clinical potential of RXC004 in cancer patients."
The company said that RXC004 has the potential to be developed in different cancers and different treatment settings
Follow News & Updates from Redx Pharma here: